|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Preclinical Experimental Therapeutics |
Alkermes, Inc., Cambridge, MA 02139
1 Address correspondence and reprint requests to Raymond T. Bartus, Ph.D., Alkermes, Inc., Senior Vice President of Pre-Clinical Research and Development, 64 Sidney St., 4th Floor, Cambridge, MA 02139.
Abstract
Accumulating evidence suggests that dexamethasone might decrease permeability of the blood-brain tumor barrier, further limiting the delivery of agents into brain tumors. The bradykinin B2 receptor agonist, Cereport® (RMP-7), selectively increases permeability of the vasculature supplying brain tumors in both animal models and humans. The present study was conducted to characterize the effects of dexamethasone on the blood-brain tumor barrier and its potential interaction with Cereport's ability to enhance penetration of radiolabeled carboplatin. Dexamethasone (1.5 mg/kg/day, twice a day) was given to RG2 glioma-bearing rats via oral gavage for 3 consecutive days. After treatment, animals received a 15-min intracarotid infusion of Cereport (4.5 µg/kg) and a bolus of [14C]carboplatin. The levels of [14C]carboplatin (nCi/g) in the tumor and nontumor regions were determined at 1, 14, or 24 h after the last dose of dexamethasone. Dexamethasone, alone, significantly decreased the levels of radiolabeled carboplatin permeating the tumor (19%), although there were no significant differences between any of the time points examined. Cereport administration significantly increased levels of carboplatin in the tumor, independent of whether or not dexamethasone was given (46% with and 49% without). Although the relative effects of Cereport on tumor carboplatin levels were not affected by dexamethasone, the absolute levels achieved with Cereport were modestly reduced (44 nCi/g versus 55.5 nCi/g of [14C]carboplatin, with and without dexamethasone, respectively). Thus, while the data support the use of Cereport as adjunctive therapy in the treatment of glioma patients, they also warn that the use of dexamethasone may reduce delivery of chemotherapeutic agents to brain tumors, even when special pharmacologic measures are employed to enhance delivery.
References
Bartus, R.T. (1999) The blood-brain barrier as a target for pharmacological modulation. Curr. Opin. Drug Discov. Dev. 2,152 -167.
Bartus, R.T., Elliott, P.J., Dean, R.L., Hayward, N.J., Nagle, T.L., Huff, M.R., Snodgrass, P.A., and Blunt, D.G. (1996a) Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol. 142,14 -28.[CrossRef][ISI][Medline]
Bartus, R.T., Elliott, P., Hayward, N., Dean, R., McEwen, E.L., and Fisher, S.K. (1996b) Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology 33,270 -278.[CrossRef][ISI][Medline]
Black, K.L. (1995) Biochemical opening of the blood-brain barrier. Adv. Drug Del. Rev. 15, 37-52.
Black, K.L., Cloughesy, T., Huang, S.C., Gobin, Y.P., Zhou, Y., Grous, J., Nelson, G., Farahani, K., Hoh, C.K., and Phelps, M. (1997) Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J. Neurosurg. 86,603 -609.[ISI][Medline]
Cloughesy, T.F., Black, K.L., Gobin, Y.P., Farahani, K., Nelson, G., Villablanca, P., Kabbinavar, F., Vinuela, F., and Wortel, C.H. (1999) Intra-arterial Cereport (RMP-7) and carboplatin: A dose escalation study for recurrent malignant gliomas. Neurosurgery 44,270 -278.[ISI][Medline]
Dean, R.L., Elliott, P.J., Nagle, T., Hayward, N., Merchant, R., and Bartus, R.T. (1996) RMP-7 increases uptake of carboplatin into rat gliomas: Comparison of three cell lines. Proc. Am. Assoc. Cancer Res. 37,303 . (Abstract)
Doctrow, S.R., Abelleira, S.M., Curry, L.A., Heller-Harrison, R.,
Kozarich, J.W., Malfroy, B., McCarroll, L.A., Morgan, K.G., Morrow, A.R.,
Musso, G.F., Smart, J.L., Straub, J.A., and Turnbull, B. (1994)
The bradykinin analog RMP-7 increases extracellular free calcium levels in rat
brain microvascular endothelial cells. J. Pharmacol. Exp.
Ther. 271,229
-237.
Elliott, P.J., Hayward, N.J., Dean, R.L., Blunt, D.G., and Bartus,
R.T. (1996a) Intravenous RMP-7 selectively increases uptake of
carboplatin into rat brain tumors. Cancer Res.
56,3998
-4005.
Elliott, P.J., Hayward, N.J., Huff, M.R., Nagle, T.L., Black, K.L., and Bartus, R.T. (1996b) Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy. Exp. Neurol. 141,214 -224.[CrossRef][ISI][Medline]
Ford, J.M., Miles, K.A., Hayball, M.P., Bearcroft, P.W., Bleehen, N.M., and Osborn, C.S. (1996) A simplified technique for measurement of bloodbrain barrier permeability using CT: Preliminary results of the effect of RMP-7. In: Faulkner, K., Carey, B., Crellin, A., and Harrison, R.M. (Eds.) Quantitative Imaging in Oncology. London: British Institute of Radiology. pp.126 -155.
French, L.A., and Galicich, J.H. (1964) The use of steroids for control of cerebral edema. Clin. Neurosurg. 10,212 -223.[Medline]
Glaser, A.W., Buxton, N., and Walker, D. (1997)
Corticosteroids in the management of central nervous system tumors.
Arch. Dis. Child. 76,76
-78.
Gregor, A., Lind, M., and Osborn, C. (1997) Intravenous RMP-7 and carboplatin: Efficacy of a new treatment for recurrent malignant glioma. Eur. J. Cancer 53 (Suppl. 8), S17. (Abstract)
Groothius, D.R., Fischer, J.M., Lapin, G., Bigner, D.D., and Vick, N.A. (1982) Permeability of different experimental brain tumor models to horseradish peroxidase. J. Neuropathol. Exp. Neurol. 41,164 -185.[ISI][Medline]
Guerin, C., Wolff, J.E., Laterra, J., Drewes, L.R., Brem, H., and Goldstein, G.W. (1992) Vascular differentiation and glucose transporter expression in rat gliomas: Effects of steroids. Ann. Neurol. 31,481 -487.[CrossRef][ISI][Medline]
Gutin, P.H. (1977) Corticosteroid therapy in patients with brain tumors. J. Natl. Cancer Inst. Monogr. 46,151 -156.
Hatam, A., Bergstrôm, M., Yu, Z.Y., Granholm, L., and Berggren, B.M. (1983) Effect of dexamethasone treatment on volume and contrast enhancement of intracranial neoplasms. J. Comput. Assist. Tomogr. 7,295 -300.[ISI][Medline]
Inamura, T., and Black, K.L. (1994) Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J. Cereb. Blood Flow. Metab. 14,862 -870.[ISI][Medline]
Inamura, T., Nomura, T., Bartus, R.T., and Black, K.L. (1994) Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors. J. Neurosurg. 81,752 -758.[ISI][Medline]
Jarden, J.O., Dhawan, V., Moeller, J., Strother, S.C., and Rottenberg, D.A. (1989) The time course of steroid action or blood-to-brain and blood-to-tumor transport of 82Rb: A positron emission tomographic study. Ann. Neurol. 25,239 -245.[CrossRef][ISI][Medline]
Koehler, P.J. (1995) Use of corticosteroids in neuro-oncology. Anticancer Drugs 6, 19-33.[Medline]
Levin, V.A., Freeman-Dove, M., and Landahl, H.D. (1975) Permeability characteristics of brain adjacent to tumors in rats. Arch. Neurol. 32,785 -791.[Abstract]
Lieberman, A., Le Brun, Y., Glass, P., Goodgold, A., Lux, W., Wise, A., and Ransohoff, J. (1977) Use of high dose corticosteroids in patients with inoperable brain tumors. J. Neurol. Neurosurg. Psychiat. 40,678 -682.[Abstract]
Long, D.M. (1970) Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J. Neurosurg. 32,127 -144.[ISI][Medline]
Luthert, P.J., Greenwood, J., Lantos, P.L., and Pratt, O.E. (1986) The effect of dexamethasone on vascular permeability of experimental brain tumors. Acta Neuropathol. (Berlin) 69,288 -294.[CrossRef][Medline]
Matsukado, K., Inamura, T., Nakano, S., Fukui, M., Bartus, R.T., and Black, K.L. (1996) Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39,125 -134.[CrossRef][ISI][Medline]
Matsukado, K., Nakano, S., Bartus, R.T., and Black, K.L. (1997) Steroids decrease uptake of carboplatin in rat gliomas-uptake improved by intracarotid infusion of bradykinin analog, RMP-7. J. Neurooncol. 34,131 -138.[CrossRef][Medline]
Matsukado, K., Sugita, M., and Black, K.L. (1998) Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res. 792,10 -15.[CrossRef][ISI][Medline]
Molnar, P., Lapin, G.D., and Groothius, D.R. (1995) The effects of dexamethasone on experimental brain tumors: 1. Transcapillary transport and blood `ow in RG-2 rat gliomas. J. Neurooncol. 25,19 -28.[CrossRef][Medline]
Nakagawa, H., Groothius, D.R., Owens, E.S., Fenstermacher, J.D., Patlak, C.S., and Blasberg, R.G. (1987) Dexamethasone effects on [125-I] albumin distribution in experimental RG-2 gliomas and adjacent brain. J. Cereb. Blood Flow Metab. 7, 687-701.[ISI][Medline]
Nelson, D.F., McDonald, J.V., Lapham, L.W., Qazi, R., and Rubin, P. (1993) Central Nervous System Tumors. In McDonald, J., Qazi, R., and Rubin, P. (Eds.), Clinical Oncology: A Multidisciplinary Approach for Physicians and Students. Seventh edition. Philadelphia: W.B. Saunders Co. pp.617 -644.
Neuwelt, E.A., and Rapoport, S.I. (1984) Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc. 43,214 -219.[ISI][Medline]
Neuwelt, E.A., Barnett, P.A., Bigner, D.D., and Frenkel, E.P.
(1982) Effects of adrenal cortical steroids and osmotic
blood-brain barrier opening on methotrexate delivery to gliomas in the rodent:
The factor of the blood-brain barrier. Proc. Natl. Acad. Sci.
U.S.A. 79,4420
-4423.
Neuwelt, E.A., Hill, S.A., and Frenkel, E.P. (1984) Osmotic blood-brain barrier modification and combination chemotherapy: Concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 15,362 -366.[ISI][Medline]
Neuwelt, E.A., Barnett, P.A., McCormick, C.I., Frenkel, E.P., and Minna, J.D. (1985) Osmotic blood-brain barrier modification: Monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal `uid and brain. Neurosurgery 17,419 -423.[ISI][Medline]
Neuwelt, E.A., Horaczek, A., and Pagel, M.A. (1990) The effect of steroids on gentamicin delivery to brain after blood-brain barrier disruption. J. Neurosurg. 72,123 -126.[ISI][Medline]
Neuwelt, E.A., Barnett, P.A., Ramsey, F.L., Hellstrom, I., Hellstrom, K.E., and McCormick, C.I. (1993) Dexamethasone decreases the delivery of tumorspecific monoclonal antibody to both intracerebral and subcutaneous tumor xenografts. Neurosurgery 33,478 -484.[ISI][Medline]
Nomura, T., Inamura, T., and Black, K.L. (1994) Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. 659, 62-66.[CrossRef][ISI][Medline]
Pellegrino, L.J., Pellegrino, A.S., and Cushman, A.J. (1986) A Stereotaxic Atlas of the Rat Brain. Third edition. New York: Plenum Press.
Posner, J. (1992) Management of brain metastases. Rev. Neurol. (Paris) 148,477 -487.[Medline]
Preston-Martin, S. (1999) Epidemiology. In Berger, M., and Wilson, C. (Eds.), The Gliomas. Philadelphia: W.B. Saunders. pp. 2-11.
Reichman, H.R., Farrell, C.L., and Del Maestro, R.F. (1986) Effects of steroids and non-steroid anti-in`ammatory agents on vascular permeability in a ray glioma model. J. Neurosurg. 65,233 -237.[ISI][Medline]
Renaudin, J., Fewer, D., Wilson, C.B., Boldrey, E.B., Calogero, J., and Enot, K.J. (1973) Dose dependency of Decadron in patients with partially excised brain tumors. J. Neurosurg. 39,302 -305.[ISI][Medline]
Shapiro, W.R., Hiesiger, E.M., Cooney, G.A., Basler, G.A., Lipschutz, L.E., and Posner, J.B. (1990) Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14-C-alpha-aminoisobutyric acid in rat C6 glioma. J. Neurooncol. 8,197 -204.[Medline]
Shibata, S. (1989) Ultrastructure of capillary walls in human brain tumors. Acta. Neuropathol. 78,561 -571.[CrossRef][Medline]
Straathof, C.S.M., van den Bent, M.J., Ma, J., Schmitz, P.I.M., Kros, J.M., Stoter, G., Vecht, C.J., and Schellens, J.H.M. (1998) The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J. Neurooncol. 37, 1-8.[CrossRef][Medline]
Straub, J.A., Akiyama, A., and Parmar, P. (1994) In vitro plasma metabolism of RMP-7. Pharmaceut. Res. 11,1673 -1676.[CrossRef][ISI][Medline]
Tjuvajev, J., Uehara, H., Desai, R., Beattie, B., Marei, C., Zhou,
Y., Kreerk, M., Koutcher, J., and Blasberg, R. (1996)
Corticotropin-releasing factor decreases vasogenic brain edema.
Cancer Res. 56,1352
-1360.
Tonolo, G., Fraser, R.,Connell, J.M., and Kenyon, C.J. (1988) Chronic low-dose infusions of dexamethasone in rats: Effects on blood pressure, body weight and plasma atrial natriuretic peptide. J. Hypertens. 6,25 -31.[ISI][Medline]
Vecht, C.J., and Verbiest, H.B.C. (1995) Use of glucocorticoids in neuro-oncology. In Wiley, R.G. (Ed.), Neurological Complications of Cancer. New York: Marcel Dekker. pp. 199-218.
Wolff, J., Guerin, C., Laterra, J., Bressler, J., Indurti, R.R., Brem, H., and Goldstein, G.W. (1993) Dexamethasone reduces vasular density and plasminogen activator activity in 9L rat brain tumors. Brain Res. 604,79 -85.[CrossRef][ISI][Medline]
Yamada, K., Ushio, Y., Hayakawa, T., Arita, N., Yamada, N., and Mogami, H. (1983) Effects of methylprednisolone on peritumoral brain edema: A quantitative autoradiographic study. J. Neurosurg. 59,612 -619.[ISI][Medline]
Yeung, W.T.I., Lee, T.Y., Del Maestro, R.F., Kozak, R., Bennett, J., and Brown, T. (1993) Effects of steroids on iopamidol blood-brain transfer constant and plasma volume in brain tumors measured with X-ray computed tomography. J. Neurooncol. 18, 53-60.
Zivlan, Y.Z., LeFauconnier, J.M., Bernard, G., and Bourre, J.M. (1988) Effect of dexamethasone on transport of alpha-aminoisobutyric acid and sucrose across the blood-brain barrier. J. Neurochem. 51,1338 -1342.[CrossRef][ISI][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
